Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 345

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 345
---
Other comprehensive income—— — — 1,397 1,397 Balance as of September 30, 202447,968,121$5 $851,490 $(620,391)$920 $232,024 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 Nine Months Ended September 30, 20252024Operating activitiesNet loss$(17,633)$(64,152)Reconciliation of net loss to net cash provided by operating activities:Stock-based compensation52,398 35,193 Depreciation and amortization18,170 17,573 Inventory reserves and firm commitment losses2,889 1,783 Amortization of debt discount and offering costs1,303 1,245 Unrealized foreign exchange gain(1,913)(1,082)Non-cash lease expense1,273 985 Other(1,019)(425)Change in operating assets and liabilities:Accounts receivable(29,047)(562)Prepaid and other current assets(11,746)(1,122)Inventory(6,166)(2,952)Other assets(4,026)(1,496)Accounts payable, accrued expenses and other liabilities46,660 30,973 Operating lease liabilities(1,383)(568)Net cash provided by operating activities49,760 15,393 Investing activitiesPurchase of investments(85,923)(77,543)Proceeds from maturities of investments61,317 7,750 Purchase of property and equipment(354)(973)Payments made for additions to intangible assets— (20,000)Net cash used in investing activities(24,960)(90,766)Financing activitiesProceeds from issuance of common stock pursuant to equity plans31,143 12,359 Net cash provided by financing activities31,143 12,359 Effect of exchange rate on cash, cash equivalents and restricted cash3,630 82 Net increase (decrease) in cash, cash equivalents and restricted cash59,573 (62,932)Cash, cash equivalents and restricted cash at beginning of period222,928 286,326 Cash, cash equivalents and restricted cash at end of period$282,501 $223,394  Supplemental disclosure of cash flow